To be used in line with NICE

First line treatment option where a DPP-4 inhibitor is indicated.

No significant clinical benefit when used in combination with Insulin – avoid using together

In line with NICE No significant clinical benefit when used in combination with Insulin – avoid using together 

In line with NICE
Linagliptin has no significant clinical benefit or renoprotective effect in patients with CKD.

Sitagliptin should be used first line at the appropriate renal dose
where a DPP4 inhibitor is indicated

No significant clinical benefit when used in combination
with Insulin – avoid using together